These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 18266604)

  • 1. Safety, pharmacokinetics, and antiviral activity of HGS004, a novel fully human IgG4 monoclonal antibody against CCR5, in HIV-1-infected patients.
    Lalezari J; Yadavalli GK; Para M; Richmond G; Dejesus E; Brown SJ; Cai W; Chen C; Zhong J; Novello LA; Lederman MM; Subramanian GM
    J Infect Dis; 2008 Mar; 197(5):721-7. PubMed ID: 18266604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults.
    Schürmann D; Fätkenheuer G; Reynes J; Michelet C; Raffi F; van Lier J; Caceres M; Keung A; Sansone-Parsons A; Dunkle LM; Hoffmann C
    AIDS; 2007 Jun; 21(10):1293-9. PubMed ID: 17545705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and clinical investigation of the relationship between CCR5 receptor occupancy and anti-HIV activity of Aplaviroc.
    Demarest JF; Sparks SS; Schell K; Shibayama S; McDanal CB; Fang L; Adkison KK; Shachoy-Clark A; Piscitelli SC
    J Clin Pharmacol; 2008 Oct; 48(10):1179-88. PubMed ID: 18676693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I study to explore the activity and safety of SCH532706, a small molecule chemokine receptor-5 antagonist in HIV type-1-infected patients.
    Pett SL; McCarthy MC; Cooper DA; MacRae K; Tendolkar A; Norris R; Strizki JM; Williams KM; Emery S
    Antivir Ther; 2009; 14(1):111-5. PubMed ID: 19320244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults.
    Jacobson JM; Saag MS; Thompson MA; Fischl MA; Liporace R; Reichman RC; Redfield RR; Fichtenbaum CJ; Zingman BS; Patel MC; Murga JD; Pemrick SM; D'Ambrosio P; Michael M; Kroger H; Ly H; Rotshteyn Y; Buice R; Morris SA; Stavola JJ; Maddon PJ; Kremer AB; Olson WC
    J Infect Dis; 2008 Nov; 198(9):1345-52. PubMed ID: 18771406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV-infected, therapy-naïve patients: results of the EPIC study (CCR100136).
    Yeni P; Lamarca A; Berger D; Cimoch P; Lazzarin A; Salvato P; Smaill FM; Teofilo E; Madison SJ; Nichols WG; Adkison KK; Bonny T; Millard J; McCarty D;
    HIV Med; 2009 Feb; 10(2):116-24. PubMed ID: 19200175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and short-term safety of 873140, a novel CCR5 antagonist, in healthy adult subjects.
    Adkison KK; Shachoy-Clark A; Fang L; Lou Y; O'Mara K; Berrey MM; Piscitelli SC
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2802-6. PubMed ID: 15980352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults.
    Jacobson JM; Lowy I; Fletcher CV; O'Neill TJ; Tran DN; Ketas TJ; Trkola A; Klotman ME; Maddon PJ; Olson WC; Israel RJ
    J Infect Dis; 2000 Jul; 182(1):326-9. PubMed ID: 10882617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and pharmacokinetics of brecanavir, a novel human immunodeficiency virus type 1 protease inhibitor, following repeat administration with and without ritonavir in healthy adult subjects.
    Reddy YS; Ford SL; Anderson MT; Murray SC; Ng-Cashin J; Johnson MA
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1202-8. PubMed ID: 17261626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 1 study of PAmAb, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers.
    Subramanian GM; Cronin PW; Poley G; Weinstein A; Stoughton SM; Zhong J; Ou Y; Zmuda JF; Osborn BL; Freimuth WW
    Clin Infect Dis; 2005 Jul; 41(1):12-20. PubMed ID: 15937757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic inhibition of R5 HIV-1 by maraviroc and CCR5 antibody HGS004 in primary cells: implications for treatment and prevention.
    Latinovic O; Le N; Reitz M; Pal R; DeVico A; Foulke JS; Redfield RR; Heredia A
    AIDS; 2011 Jun; 25(9):1232-5. PubMed ID: 21505306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals.
    Irlbeck DM; Amrine-Madsen H; Kitrinos KM; Labranche CC; Demarest JF
    AIDS; 2008 Jul; 22(12):1425-31. PubMed ID: 18614865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection.
    Smith PF; Ogundele A; Forrest A; Wilton J; Salzwedel K; Doto J; Allaway GP; Martin DE
    Antimicrob Agents Chemother; 2007 Oct; 51(10):3574-81. PubMed ID: 17638699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel CCR5 monoclonal antibodies with potent and broad-spectrum anti-HIV activities.
    Ji C; Brandt M; Dioszegi M; Jekle A; Schwoerer S; Challand S; Zhang J; Chen Y; Zautke L; Achhammer G; Baehner M; Kroetz S; Heilek-Snyder G; Schumacher R; Cammack N; Sankuratri S
    Antiviral Res; 2007 May; 74(2):125-37. PubMed ID: 17166600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiviral activity and safety of aplaviroc with lamivudine/zidovudine in HIV-infected, therapy-naive patients: the ASCENT (CCR102881) study.
    Currier J; Lazzarin A; Sloan L; Clumeck N; Slims J; McCarty D; Steel H; Kleim JP; Bonny T; Millard J;
    Antivir Ther; 2008; 13(2):297-306. PubMed ID: 18505181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults.
    Jacobson JM; Lalezari JP; Thompson MA; Fichtenbaum CJ; Saag MS; Zingman BS; D'Ambrosio P; Stambler N; Rotshteyn Y; Marozsan AJ; Maddon PJ; Morris SA; Olson WC
    Antimicrob Agents Chemother; 2010 Oct; 54(10):4137-42. PubMed ID: 20660677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of food on the antiviral activity of didanosine enteric-coated capsules: a pilot comparative study.
    Hernández-Novoa B; Antela A; Gutiérrez C; Pérez-Molina JA; Pérez-Elías MJ; Dronda F; Moreno A; Casado JL; Page C; Pumares M; Galán JC; Moreno S
    HIV Med; 2008 Apr; 9(4):187-91. PubMed ID: 18298579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A passive immunotherapy, (PE)HRG214, in patients infected with human immunodeficiency virus: a phase I study.
    Dezube BJ; Proper J; Zhang J; Choy VJ; Weeden W; Morrissey J; Burns EM; Dixon JD; O'Loughlin C; Williams LA; Pickering PJ; Crumpacker CS; Gelder FB
    J Infect Dis; 2003 Feb; 187(3):500-3. PubMed ID: 12552435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, tolerability, and pharmacokinetic effects of thalidomide in patients infected with human immunodeficiency virus: AIDS Clinical Trials Group 267.
    Wohl DA; Aweeka FT; Schmitz J; Pomerantz R; Cherng DW; Spritzler J; Fox L; Simpson D; Bell D; Holohan MK; Thomas S; Robinson W; Kaplan G; Teppler H;
    J Infect Dis; 2002 May; 185(9):1359-63. PubMed ID: 12001058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-term randomized proof-of-principle trial of TMC278 in patients with HIV type-1 who have previously failed antiretroviral therapy.
    Arastéh K; Rieger A; Yeni P; Pozniak A; Boogaerts G; van Heeswijk R; de Béthune MP; Peeters M; Woodfall B
    Antivir Ther; 2009; 14(5):713-22. PubMed ID: 19704175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.